title: [Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
abstract: OBJECTIVE
  The purpose of the present article was to evaluate indications, regimens, treatment modalities, and predictive factors of response to treatment in locally advanced squamous cell carcinoma of the head and neck (SCCHN).
  
  
  METHODS
  An expert panel including otolaryngology and head and neck surgery specialists, oncologists, radiotherapists and biologists analyzed the literature providing a synthesis and giving some recommendations.
  
  
  RESULTS
  Findings from the main randomized phase III trials highlight that the TPF regimen (docetaxel, cisplatin, fluorouracil) represent a preferential option when induction chemotherapy is indicated in either operable or non-operable patients. Given the potential fragility of patients presenting with SCCHN, treatment modalities in routine use require applying preventive measures and tailored follow-up according to each patient's profile. As regards predictive factors of response to TPF regimen, no factor is currently validated, but ongoing trials should provide better knowledge.
  
  
  CONCLUSIONS
  Progresses in induction chemotherapy have allowed improving the prognosis of patients with locally advanced SCCHN. The TPF regimen represents a major improvement in this indication, and ongoing strategic clinical trials should refine its indications.
authors.affiliation: Département de Radiothérapie, Centre René-Gauducheau, Boulevard Jacques-Monod, 44805 Nantes Saint-Herblain, France.
authors.forename: E
authors.initials: E
authors.lastname: Bardet
authors.forename: J
authors.initials: J
authors.lastname: Bourhis
authors.forename: L
authors.initials: L
authors.lastname: Cals
authors.forename: J
authors.initials: J
authors.lastname: Fayette
authors.forename: J
authors.initials: J
authors.lastname: Guigay
authors.forename: S
authors.initials: S
authors.lastname: Hans
authors.forename: J Lacau
authors.initials: JL
authors.lastname: Saint-Guily
authors.forename: F
authors.initials: F
authors.lastname: Lagarde
authors.forename: B
authors.initials: B
authors.lastname: Lallemant
authors.forename: G
authors.initials: G
authors.lastname: Milano
authors.forename: F
authors.initials: F
authors.lastname: Rolland
authors.forename: J-L
authors.initials: JL
authors.lastname: Lefebvre
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000378:metabolism; D017326:Clinical Trials, Phase III as Topic; D032921:Consensus; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000378:metabolism; D005602:France; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction / Q000379:methods; D043823:Taxoids / Q000008:administration & dosage / Q000378:metabolism
chemical_list: D015415:Biomarkers; D043823:Taxoids; D002945:Cisplatin; D005472:Fluorouracil